639 related articles for article (PubMed ID: 23362959)
1. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
3. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
Li WW; Wang XY; Zheng RL; Yan HX; Cao ZX; Zhong L; Wang ZR; Ji P; Yang LL; Wang LJ; Xu Y; Liu JJ; Yang J; Zhang CH; Ma S; Feng S; Sun QZ; Wei YQ; Yang SY
J Med Chem; 2012 Apr; 55(8):3852-66. PubMed ID: 22452518
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
6. Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model.
Li GB; Ma S; Yang LL; Ji S; Fang Z; Zhang G; Wang LJ; Zhong JM; Xiong Y; Wang JH; Huang SZ; Li LL; Xiang R; Niu D; Chen YC; Yang SY
J Med Chem; 2016 Sep; 59(18):8293-305. PubMed ID: 27535613
[TBL] [Abstract][Full Text] [Related]
7. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.
Zhang CH; Zheng MW; Li YP; Lin XD; Huang M; Zhong L; Li GB; Zhang RJ; Lin WT; Jiao Y; Wu XA; Yang J; Xiang R; Chen LJ; Zhao YL; Cheng W; Wei YQ; Yang SY
J Med Chem; 2015 May; 58(9):3957-74. PubMed ID: 25835317
[TBL] [Abstract][Full Text] [Related]
9. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
Ma S; Yang LL; Niu T; Cheng C; Zhong L; Zheng MW; Xiong Y; Li LL; Xiang R; Chen LJ; Zhou Q; Wei YQ; Yang SY
Sci Rep; 2015 Oct; 5():15646. PubMed ID: 26497577
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anticancer and radioprotective activities of some new pyrazolo[3,4-d]pyrimidines containing amino acid moieties.
Ghorab MM; Ragab FA; Noaman E; Heiba HI; Aboulmagd SA
Arzneimittelforschung; 2009; 59(2):96-103. PubMed ID: 19338140
[TBL] [Abstract][Full Text] [Related]
11. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
12. Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.
Miyazaki Y; Tang J; Maeda Y; Nakano M; Wang L; Nolte RT; Sato H; Sugai M; Okamoto Y; Truesdale AT; Hassler DF; Nartey EN; Patrick DR; Ho ML; Ozawa K
Bioorg Med Chem Lett; 2007 Mar; 17(6):1773-8. PubMed ID: 17276055
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues.
Yuan L; Song C; Li C; Li Y; Dong L; Yin S
Eur J Med Chem; 2013 Sep; 67():152-7. PubMed ID: 23851116
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
[TBL] [Abstract][Full Text] [Related]
16. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
17. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
[TBL] [Abstract][Full Text] [Related]
20. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C
Oh C; Kim H; Kang JS; Yun J; Sim J; Kim HM; Han G
Bioorg Med Chem Lett; 2017 Feb; 27(3):496-500. PubMed ID: 28043794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]